California Affordable Drug Manufacturing Act of 2020: opioid antagonists.

Summary

The bill adds a new section to the Health and Safety Code that prevents California state agencies from awarding sole‑source contracts for naloxone or other FDA‑approved opioid‑reversal drugs to firms that have entered multistate settlement agreements over the opioid crisis. Any contract that violates this rule is void and unenforceable, and the restriction applies retroactively to contracts signed before Jan. 1, 2026. The measure seeks to promote competition and avoid non‑competitive deals with settlement parties.

AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.

Hearings

• Health Committee Hearing
  Health · Apr 29, 2025

History

1. Feb 2, 2026From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.
2. Jan 31, 2026Died pursuant to Art. IV, Sec. 10(c) of the Constitution.
3. Apr 29, 2025In committee: Set, first hearing. Failed passage. Reconsideration granted.
4. Mar 13, 2025Referred to Com. on HEALTH.
5. Feb 24, 2025Read first time.
6. Feb 22, 2025From printer. May be heard in committee March 24.
7. Feb 21, 2025Introduced. To print.

Sponsors

• Patterson · sponsor

Bill text

Opens the legislature’s own copy.

Similar bills in other states

Loading the map of where bills like this one were filed.

Topics

Share